Novo Nordisk Seeks Injunction Against Eli Lilly Over Weight-Loss Drug Ads

Novo Nordisk said it asked a U.S. court to preliminarily halt rival Eli Lilly from advertising weight-loss drugs, days after accusing the Indianapolis drugmaker of using deceptive advertising to mislead consumers in a lawsuit.

Details of the Action

Friday's preliminary injunction request, filed in the District of New Jersey, escalates legal proceedings initiated earlier this week. Novo has now asked the court to stop Eli Lilly from advertising its GLP-1 drugs while the lawsuit proceeds.

Company's Position

Novo Nordisk alleges that Eli Lilly's advertisements contain misleading claims about the efficacy of its weight-loss drugs, potentially harming consumers and creating unfair competition. Eli Lilly has not yet issued an official response to the injunction request.

Precedents and Context

The case comes amid intense competition between the two companies in the rapidly growing GLP-1 market for obesity and diabetes treatments. Novo Nordisk filed the initial lawsuit earlier this week and is now seeking to expedite proceedings through the injunction.

Potential Financial Impact

If granted, the injunction could hinder Eli Lilly's ability to promote its drugs such as Mounjaro and Zepbound, potentially impacting sales in this lucrative segment. Conversely, it may protect Novo Nordisk's market share for its drugs like Ozempic and Wegovy.